PegBio Co., Ltd.
派格生物醫藥(杭州)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2565)

INSIDE INFORMATION ANNOUNCEMENT

VISEPEGENATIDE INJECTION INCLUDED IN THE PUBLICATION OF SUPPLEMENTAL DRUG INFORMATION FOR THE SECOND BATCH OF REFERENCE DRUG PRE-COMMUNICATION IN 2026

This announcement is made by PegBio Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**Inside Information Provisions**").

The board of directors (the "**Board**") of the Company is pleased to announce that, according to the "Publication of Supplemental Drug Information for the Second Batch of Reference Drug Pre-communication in 2026" published by the National Healthcare Security Administration on May 27, 2026, the relevant materials in respect of Visepegenatide injection submitted by the Company have, following feedback, been confirmed to meet the application requirements for the second batch of reference drug pre-communication in 2026, and have been included in the scope of this publication of supplemental drug information. The publication period is from May 27, 2026 to June 2, 2026.

The inclusion in the scope of this supplemental publication marks a phased progress of Visepegenatide injection in the relevant work of national medical insurance reference drug pre-communication, which is conducive to the orderly advancement of subsequent work relating to reference drug confirmation, medical insurance access and payment management. The Board considers that such progress reflects the continued advancement of the Company's core product in post-launch access work, and is also conducive to enhancing the future clinical accessibility, payment accessibility and commercialization foundation of the product.

Visepegenatide injection is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently developed by the Company, which has been approved by the National Medical Products Administration for glycemic control in adult patients with type 2 diabetes. The product adopts a once-weekly, fixed-dose administration regimen, without the need for dose titration, and has characteristics such as a clear administration pathway, relatively good patient compliance and suitability for long-term chronic disease management. The Company will continue to advance the market access, academic promotion and commercialization implementation of Visepegenatide injection, so as to further enhance the clinical value and accessibility of the product for patients with type 2 diabetes in China.

Shareholders of the Company and potential investors should note that this publication represents a phased progress in the relevant procedures of national medical insurance reference drug pre-communication, and does not constitute confirmation that the product has completed reference drug confirmation, been included in the National Reimbursement Drug List or obtained any final payment arrangement. Relevant subsequent progress shall remain subject to the official notices, publications or final results of the competent authorities. The Company will make further announcement(s) as and when appropriate in accordance with applicable laws and regulations and the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PegBio Co., Ltd.
Michael Min XU
Chairman of the Board, Executive Director and General Manager

Hong Kong, May 28, 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun ZHANG and Dr. Yangyang CHEN as independent non-executive directors.